CA2484656A1 - Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases - Google Patents

Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases Download PDF

Info

Publication number
CA2484656A1
CA2484656A1 CA002484656A CA2484656A CA2484656A1 CA 2484656 A1 CA2484656 A1 CA 2484656A1 CA 002484656 A CA002484656 A CA 002484656A CA 2484656 A CA2484656 A CA 2484656A CA 2484656 A1 CA2484656 A1 CA 2484656A1
Authority
CA
Canada
Prior art keywords
lactoferrin
subject
composition
cells
hyperproliferative disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002484656A
Other languages
English (en)
French (fr)
Inventor
Atul Varadhachary
Rick Barsky
Frederica Pericle
Karel Petrak
Yenyun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2484656A1 publication Critical patent/CA2484656A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002484656A 2002-05-10 2003-05-09 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases Abandoned CA2484656A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US37944102P 2002-05-10 2002-05-10
US37944202P 2002-05-10 2002-05-10
US37947402P 2002-05-10 2002-05-10
US60/379,474 2002-05-10
US60/379,441 2002-05-10
US60/379,442 2002-05-10
PCT/US2003/014789 WO2003099323A1 (en) 2002-05-10 2003-05-09 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases

Publications (1)

Publication Number Publication Date
CA2484656A1 true CA2484656A1 (en) 2003-12-04

Family

ID=29424524

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002484656A Abandoned CA2484656A1 (en) 2002-05-10 2003-05-09 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases

Country Status (11)

Country Link
US (5) US7901879B2 (enExample)
EP (2) EP2286827A1 (enExample)
JP (2) JP4685443B2 (enExample)
CN (2) CN100467060C (enExample)
AT (1) ATE519499T1 (enExample)
AU (2) AU2003239393A1 (enExample)
CA (1) CA2484656A1 (enExample)
CY (1) CY1111999T1 (enExample)
DK (1) DK1507554T3 (enExample)
PT (1) PT1507554E (enExample)
WO (2) WO2003094952A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
EP2286827A1 (en) 2002-05-10 2011-02-23 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
DK2298338T3 (da) * 2002-09-16 2012-09-24 Agennix Inc Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
JP4795021B2 (ja) * 2002-12-06 2011-10-19 エイジェニックス インコーポレイテッド 敗血症治療における経口用ラクトフェリン
US7592306B2 (en) * 2002-12-10 2009-09-22 Agennix, Inc. Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
US7323443B2 (en) * 2002-12-12 2008-01-29 Agennix Inc. Lactoferrin in the reduction of pain
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20050075277A1 (en) * 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
GB0413954D0 (en) * 2004-06-22 2004-07-28 Altunkaya Ali Compositions for topical treatment
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
CA2587727A1 (en) * 2004-11-19 2006-05-26 Jagat Rakesh Kanwar Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
WO2007022537A2 (en) * 2005-08-19 2007-02-22 Agennix Incorporated Use of lactoferrin as a chemokine and a chemotactic modulator
US9037230B2 (en) * 2006-03-03 2015-05-19 Oncosec Medical Incorporated Method and device for treating microscopic tumors remaining in tissues following surgical resection
CN101472612B (zh) * 2006-06-14 2011-06-08 纽崔西亚公司 包含甘氨酸和乳铁蛋白的抗炎组合物及其应用
WO2010033425A2 (en) * 2008-09-19 2010-03-25 Nestec S.A. Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
WO2010112988A1 (en) * 2009-01-28 2010-10-07 Jean-Paul Perraudin Method for production of lactoferrin
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
JP2015067560A (ja) * 2013-09-27 2015-04-13 国立大学法人広島大学 ラクトフェリンを含有する癌転移抑制剤
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
WO2015089316A1 (en) * 2013-12-12 2015-06-18 Cornell University Methods for preventing and treating oral cancers
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
CN106174462A (zh) * 2016-04-17 2016-12-07 马鞍山市志诚科技有限公司 一种防治血管瘤的营养配方纳米颗粒及制备加工方法
JPWO2018079701A1 (ja) * 2016-10-28 2019-09-19 株式会社Ｎｒｌファーマ ラクトフェリン活性を有するタンパク質を含む、抗ガン治療補助剤
CN111544579B (zh) * 2020-03-13 2026-04-10 中国农业科学院北京畜牧兽医研究所 一种抗癌症的药物组合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6351337A (ja) * 1986-08-22 1988-03-04 Snow Brand Milk Prod Co Ltd 抗腫瘍剤
US4977137B1 (en) 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5849881A (en) 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
US6100054A (en) 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5766939A (en) 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5571691A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5198419A (en) 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
AU664561B2 (en) 1991-06-21 1995-11-23 University Of Cincinnati, The Orally administrable therapeutic proteins and method of making
JP3184923B2 (ja) * 1992-01-08 2001-07-09 ビオ セレ ラボラトワール エス ア 抗リウマチ剤
ZA932568B (en) * 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5679807A (en) * 1995-01-30 1997-10-21 Hauser, Inc. Preparation of taxol and docetaxel through primary amines
JPH08217693A (ja) * 1995-02-17 1996-08-27 Yoshihisa Naito 新規医薬組成物
JP3888707B2 (ja) * 1996-01-22 2007-03-07 森永乳業株式会社 血管新生病治療剤
JP3496387B2 (ja) 1996-01-23 2004-02-09 花王株式会社 毛髪化粧料
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
JP2001504447A (ja) * 1996-08-12 2001-04-03 エイプラス サイエンス インベスト アーベー ラクトフェリンおよび／またはラクトフェリシンでの、感染、炎症および／または腫瘍の処置および予防
JP2002515893A (ja) * 1997-02-03 2002-05-28 ファーミング インテレクチュアル プロパティ ビーブイ ヒトラクトフェリンおよびその改変体の有用な特性
ATE297755T1 (de) 1997-04-10 2005-07-15 Agennix Inc Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
ATE259654T1 (de) * 1998-06-26 2004-03-15 Nutricia Nv Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
JP2000229881A (ja) * 1999-02-10 2000-08-22 Morinaga Milk Ind Co Ltd 癌疾患の予後改善剤
RU2165769C1 (ru) 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
US20030096736A1 (en) 2001-05-09 2003-05-22 Kruzel Marian L. Lactoferrin for age related disorders in humans
EP2286827A1 (en) * 2002-05-10 2011-02-23 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
DK2298338T3 (da) 2002-09-16 2012-09-24 Agennix Inc Lactoferrin-sammensætninger og fremgangsmåder til behandling af hudsår
AU2004289170B2 (en) * 2003-06-06 2009-12-17 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
US20050075277A1 (en) 2003-07-10 2005-04-07 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
CA2587727A1 (en) 2004-11-19 2006-05-26 Jagat Rakesh Kanwar Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
JP2007233064A (ja) 2006-03-01 2007-09-13 Bitsign:Kk 表示システム及び表示器

Also Published As

Publication number Publication date
WO2003094952A1 (en) 2003-11-20
JP5156084B2 (ja) 2013-03-06
CY1111999T1 (el) 2015-11-04
US7901879B2 (en) 2011-03-08
EP2286827A1 (en) 2011-02-23
WO2003099323A1 (en) 2003-12-04
CN1668325A (zh) 2005-09-14
US20100137208A1 (en) 2010-06-03
US20040009895A1 (en) 2004-01-15
DK1507554T3 (da) 2011-11-21
JP4685443B2 (ja) 2011-05-18
CN100467059C (zh) 2009-03-11
AU2003273182B8 (en) 2009-05-07
US20040082504A1 (en) 2004-04-29
JP2011079858A (ja) 2011-04-21
HK1083203A1 (zh) 2006-06-30
US20120276126A1 (en) 2012-11-01
EP1507554A4 (en) 2007-05-09
EP1507554A1 (en) 2005-02-23
AU2003239393A1 (en) 2003-11-11
ATE519499T1 (de) 2011-08-15
US8242079B2 (en) 2012-08-14
JP2005533029A (ja) 2005-11-04
AU2003273182B2 (en) 2009-04-23
EP1507554B1 (en) 2011-08-10
CN1668326A (zh) 2005-09-14
US20110076295A1 (en) 2011-03-31
PT1507554E (pt) 2011-11-21
AU2003273182A1 (en) 2003-12-12
CN100467060C (zh) 2009-03-11
HK1080722A1 (zh) 2006-05-04

Similar Documents

Publication Publication Date Title
US8242079B2 (en) Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
ES2556765T5 (es) Soporte nutricional para prevenir o moderar la parálisis de la médula ósea durante el tratamiento anticáncer
US20110110983A1 (en) Lactoferrin as an adjuvant in cancer vaccines
JP2015131829A (ja) 癌性腫瘍からの骨髄毒性を阻止又は軽減するための栄養支援
JP6773269B2 (ja) 放射線療法および／または化学療法を受けている腫瘍患者における粘膜炎の治療における使用のためのアミノ酸を備える組成物
EP0942741B1 (en) Lectin compositions and uses thereof
ES2368214T3 (es) Lactoferrina en el tratamiento de neoplasmas malignos y de otras enfermedades hiperproliferativas.
HK1080722B (en) The use of lactoferrin in the treatment of malignant neoplasms
HK1083203B (en) The use of intratumorally administered lactoferrin in the treatment of malignant neoplasms
Healy et al. An Investigation into use of Natural Mistletoe Extracts and their Formulations as Potential Anti-Cancer Treatments in Human Carcinomas

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140606